STO · HEART.ST
Scandinavian Real Heart AB (Publ)
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
Loading market information…
STO · ICO.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 03:51 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Iconovo AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 31.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Iconovo AB (publ)’s next earnings report is currently expected on Feb 26, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Iconovo AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 467.00K-98.93% vs estimate |
| Q4 2024 | Feb 27, 2025 | -SEK 0.59 | SEK 986.00K-73.35% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
SEK 12.65-SEK 0.40 (-3.07%)
SciBase Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.57% below the high.
SEK 8.00+SEK 0.12 (+1.52%)
Arcoma AB’s quoted price sits in the lower half of its reported 52-week range, 20.4% below the high.
SEK 0.37+SEK 0.05 (+15.94%)
Biovica International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
SEK 3.83+SEK 0.03 (+0.66%)
Active Biotech AB’s quoted price sits in the lower half of its reported 52-week range, 59.44% below the high.
SEK 0.33-SEK 0.00 (-0.6%)
IDL Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.17% below the high.
SEK 1.57+SEK 0.01 (+0.32%)
Pila Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.4% below the high.
SEK 0.04-SEK 0.03 (-36.78%)
Immunovia AB’s quoted price sits in the lower half of its reported 52-week range, 87.62% below the high.
